Stocksigma LogoStocksigma Logo

Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore

Tavexia Lifecare's Board approved the acquisition of a 60% controlling stake in unlisted Meyonex Pharmaceuticals on 7th Oct'26 for an all-cash

Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore

Sattva Sukun Lifecare Ltd · Outcome · 08 Oct 2026, 4:13 am

Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharmaceuticals for ₹67.19 Crore Tavexia Lifecare's Board approved the acquisition of a 60% controlling stake in unlisted Meyonex Pharmaceuticals on 7th Oct'26 for an all-cash consideration of ₹67.19 Cr. The company will subscribe to 2,09,97,180 fresh equity shares at an issue price of ₹32 per share. To finance the acquisition, the Board granted in-principle approval to raise funds through the issuance of securities, including equity, warrants, or debt, via preferential allotment or rights issue. Meyonex reported FY25 turnover of ₹10.79 Cr compared to ₹13.32 Cr in FY24.

Original exchange filing (PDF)

More announcements from Sattva Sukun Lifecare Ltd

All Sattva Sukun Lifecare Ltd announcements